Mylan Receives CRL for Generic Advair Diskus From the FDA

by Zacks Equity Research Published on March 31,2017

Mylan N.V. (MYL) recently suffered a huge setback when it received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus.

• RHHBY Quick QuoteRHHBYPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Amgen's Leukemia Drug Accepted for Priority Review by FDA

by Zacks Equity Research Published on March 30,2017

Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.

• AMGN Quick QuoteAMGNPositive Net Change

Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe

by Zacks Equity Research Published on March 28,2017

Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.

• PFE Quick QuotePFEPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe

by Zacks Equity Research Published on March 27,2017

Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).

• NVS Quick QuoteNVSPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma

by Zacks Equity Research Published on March 27,2017

Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).

• PFE Quick QuotePFEPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval

by Zacks Equity Research Published on March 24,2017

Pfizer, Inc. (PFE) and German partner Merck KGaA's investigational cancer treatment, avelumab, was approved by the FDA for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer.

• PFE Quick QuotePFEPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

The Zacks Analyst Blog Highlights: Berkshire Hathaway, Amgen, Walgreens Boots Alliance, General Electric and Carnival

by Zacks Equity Research Published on March 24,2017

The Zacks Analyst Blog Highlights: Berkshire Hathaway, Amgen, Walgreens Boots Alliance, General Electric and Carnival

• BRK.B Quick QuoteBRK.BPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• WBA Quick QuoteWBANegative Net Change

Stock Research Reports for Amgen, Berkshire & Walgreens

by Sheraz Mian Published on March 23,2017

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Amgen, Inc. (AMGN) and Walgreens Boots Alliance Inc (WBA).

• PG Quick QuotePGPositive Net Change
• WBA Quick QuoteWBANegative Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• BRK.B Quick QuoteBRK.BPositive Net Change

Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

by Arpita Dutt Published on March 22,2017

Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.

• REGN Quick QuoteREGNNegative Net Change
• GILD Quick QuoteGILDNegative Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• BIIB Quick QuoteBIIBPositive Net Change

3 Biotech Stocks That Are Broker Favorites

by Arpita Dutt Published on March 21,2017

These 3 biotech stocks have been given a Strong Buy or Buy rating by 80% or more brokers and sport a favorable Zacks Rank #1 (Strong Buy) or #2 (Buy).

• AMGN Quick QuoteAMGNPositive Net Change
• BIIB Quick QuoteBIIBPositive Net Change
• CLLS Quick QuoteCLLSNegative Net Change
• BPMC Quick QuoteBPMCPositive Net Change

Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop

by Zacks Equity Research Published on March 20,2017

Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.

• SNY Quick QuoteSNYNegative Net Change
• REGN Quick QuoteREGNNegative Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• SMMT Quick QuoteSMMTNegative Net Change

What are Sanofi's (SNY) Strengths and Challenges in 2017?

by Zacks Equity Research Published on March 17,2017

We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.

• SNY Quick QuoteSNYNegative Net Change
• LLY Quick QuoteLLYPositive Net Change
• REGN Quick QuoteREGNNegative Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China

by Zacks Equity Research Published on March 16,2017

Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate

• PFE Quick QuotePFEPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

Does Amgen Offer a Great Value Buying Opportunity Right Now?

by Zacks Equity Research Published on March 16,2017

Is Amgen a great pick from the value Investor's perspective right now? Read on to know more.

• AMGN Quick QuoteAMGNPositive Net Change

Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data

by Arpita Dutt Published on March 16,2017

The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.

• REGN Quick QuoteREGNNegative Net Change
• GILD Quick QuoteGILDNegative Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication

by Zacks Equity Research Published on March 15,2017

Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.

• PFE Quick QuotePFEPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Amgen's Repatha Meets Primary Endpoint in Phase III Study

by Zacks Equity Research Published on March 14,2017

Amgen, Inc. (AMGN) announced positive data from a phase III study evaluating Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol (LDL-C).

• SNY Quick QuoteSNYNegative Net Change
• REGN Quick QuoteREGNNegative Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?

by Zacks Equity Research Published on March 10,2017

Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.

• SNY Quick QuoteSNYNegative Net Change
• REGN Quick QuoteREGNNegative Net Change
• AMGN Quick QuoteAMGNPositive Net Change

J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research Published on March 08,2017

J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day

• EHTH Quick QuoteEHTHNegative Net Change
• PFE Quick QuotePFEPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Novartis (NVS) Reports Positive Data on Biosimilar Humira

by Zacks Equity Research Published on March 07,2017

Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbVie's (ABBV) Humira.

• NVS Quick QuoteNVSPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View

by Zacks Equity Research Published on March 02,2017

Shares of Mylan N.V.'s (MYL) were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions.

• RHHBY Quick QuoteRHHBYPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Pricing to Remain Pharma Headline Risk in 2017

by Arpita Dutt Published on March 01,2017

Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now.

• ABBV Quick QuoteABBVPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• GILD Quick QuoteGILDNegative Net Change

by Zacks Equity Research Published on February 28,2017

• JNJ Quick QuoteJNJPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Pharma Industry Outlook - February/March 2017

by Arpita Dutt Published on February 27,2017

The sector is showing signs of recovery with the NYSE ARCA Pharmaceutical Index gaining 5.1% while the NASDAQ Biotechnology Index is up 7.3%.

• AMGN Quick QuoteAMGNPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• GSK Quick QuoteGSKPositive Net Change

Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates

by Zacks Equity Research Published on February 24,2017

Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.

• NVS Quick QuoteNVSPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• LGND Quick QuoteLGNDPositive Net Change
• CLLS Quick QuoteCLLSNegative Net Change